PODXL2 Antibodies

Podocalyxin-like protein 2 (PODXL2)

Acts as a ligand for vascular selectins. Mediates rapid rolling of leukocytes over vascular surfaces through high affinity divalent cation-dependent interactions with E-, P- and L- selectins.

.

Gene Information

Human
Gene Name:	PODXL2
Uniprot:	Q9NZ53
Entrez:	50512

Family

Belongs to:
podocalyxin family

Alternative Names

Endoglycan; PODLX2; podocalyxin-like 2; podocalyxin-like protein 2; PODXL2

Molecular Weight

Mass (kDA):
65.076 kDA

Genomic Context

Human
Location:	3q21.3
Sequence:	3; NC_000003.12 (127629185..127672802)

Tissue Specificity

Expressed in T-cells, B-cells and monocytes. Expression is higher on memory and germinal center cells than on naive B-cells (at protein level). Highly expressed in brain. Moderately expressed in pancreas, kidney and lymphoid node. Weakly expressed in liver. Detected in both endothelial cells and CD34+ bone marrow cells.

Subcellular Localizations

Membrane; Single-pass type I membrane protein.

Diseases

• Facial Paralysis
• Paresis
• Facial Nerve Diseases
• Facial Paresis
• Mobius Syndrome

PTMs

• Disulfide bond
• Glycoprotein

• Phosphoprotein
• Sulfation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/PODXL2

Boster Bio - Best Uses Of The PODXL2 Marker

The PODXL2 CSC marker promotes cell growth and migration. In addition, the PODXL2 protein can predict protein-protein interactions. Boster Bio provides a wide range products and services for scientists and researchers. Its customer support team is available round the clock to answer questions about its products. Customers also have access to technical resources at no cost.

PODXL2 can be used as a CSC marker

Podocalyxin-like protein 2 (PODXL2) is a member of the cluster of differentiation 34 (CD34) family, which is associated with HSCs and hematopoethelial cells. It regulates expression in cancer cells of the hippo–YAP Signaling Pathway. CSC markers such as PODXL2 are used to help distinguish between leukemia and other types of cancer.

Recent research revealed that PODXL2 was a valid CSC marker. Its promoter-driven GFP can also be used to distinguish CSCs form other types. This reporter, also known NANOG -GFP, was helpful in identifying triple negative breast cancer CSCs. Similar reporters have been constructed by other groups, including one that expressed Luciferase.

The PODXL2 genes is associated with breast carcinoma recurrence and stemness. A Desmedt dataset compares patients with and without recurrence at one year. The STRING databank shows a protein interaction network (PODXL2) Different types of evidence can be represented by the colored lines. The network is composed of experimental evidence and text-mining and coexpression research. qPCR analysis in BT483 cells revealed that PODXL2 has been associated with breast carcinoma recurrence, and stemness.

CD133 (PROM1) can also be used to identify CSCs. This marker can be used for brain tumors and gliomas. However, there have been contradictory results about this marker's utility. Other lung cancer markers that are included in the CD133 list include EpCAM, CD44 and TIM3 or PDXL2.

In contrast, a study of CD44 and PODXL2 expression in primary breast tumours found that PODXL2 is a C-SC marker that can differentiate them from other tumor cells. In addition to the PODXL2 CSC marker, CD44 is also an independent predictor of cancer outcome in patients with breast cancer. However, there are other CSC markers that are more specific.

It encourages cell proliferation

Boster Bio PODXL2 marks are well-known to be involved in breast cancer. It has been shown that this gene regulates anchorage-independent cell proliferation. It is also involved in phosphorylation of paxillin, which is a key component of cell migration and anchorage-independent cell proliferation. This finding is controversial due to the insufficient understanding of the exact mechanisms that PODXL2 is expressed in breast carcinoma.

In addition, PODXL2 is a member of the CD34 family and is a transmembrane mucin with a PDZ domain. This protein is involved in intracellular signal transduction, which is linked to poor outcomes in breast carcinoma. If cells have high levels PODXL2, they are less able to migrate and exhibit reduced expression of Rac1 or p-paxillin. Additionally, SCs are less likely to proliferate and migrate if PODXL2 is knocked down in cancer cells.

This gene is present in both primary and metastatic breast carcinomas. Patients with breast cancer who have a recurrence within one year of their surgery have higher levels of PODXL2. These data suggest that PODXL2 could be a therapeutic target for breast cancer treatment. This research has raised the stakes for the development of breast cancer immunotherapy. It is an important part of cancer research.

PODXL2 is a marker of apoptosis. This gene has a strong correlation to poor overall survival in breast carcinoma. It is therefore important to examine the relationship between PODXL2's mRNA expression and disease-free survival. The PODXL2 gene expression levels in breast cancer tissues are higher than normal tissues. Excellent correlation exists between mRNA levels.

It promotes cell-migration

Breast cancer migration and metastasis are linked to the PODXL2 protein. It also influences chemoresistance, and is a key co-activator with PDZ domain binding kinases. It plays a pivotal role in the regulation of stemness-regulated pathways and cell migration. This marker is crucial for understanding breast carcinoma and its physiology.

Breast cancer cells that express PODXL2 are more likely to recur. This could be a potential therapeutic target. PODXL2 levels are high in patients suffering from recurrent breast carcinoma. It was also found that breast cancer cells with higher levels of PODXL2 expression had a lower mortality rate and a better prognostic indicator. PODXL2 expression was linked to recurrence within one-year of surgery.

Despite its low expression levels, PODXL2 was found high in breast carcinoma. PODXL2 expression was also higher in metastatic breast carcinoma than in primary cancers. In addition, breast cancer cells showed high expression levels of PODXL2 protein, which was found to be consistent with the results of two primary antibodies. These results support the idea that PODXL2 plays a critical role in breast cancer progression.

To further test the PODXL2 gene, the scientists employed a light microscope to capture images of the culture plate. The distance traveled by each layer of cells was calculated by subtracting the distance at 0 from 48 hours. This distance is then subtracted from the distance at 48 hours. It is clear that PODXL2 promotes cell migration. Cell migration can be used to monitor the progression cancer cells.

It predicts protein-protein interactions

The PODXL2 is a PPI (protein-protein interaction), gene. It can help identify the interactions between proteins. Many genomic features can be used to predict interaction between protein-protein proteins. These include similarities in the GO process and function annotations as well as correlations in gene expression and participation in common regulatory module. The PODXL2 gene can also be a ligand to a variety of proteins that may be involved in cellular function.

Multiple functions have been linked to the PODXL2 gene, including the ability detect the presence of the protein in cell membranes. It is an essential component in the immune system and has been linked to inflammation. PODXL2 is a gene that is often found in many diseases. It is crucial for the identification potential drug candidates. PPI prediction is difficult and there have been many studies that show that PODXL2's results are not always reliable.

The PODXL2 gene encodes an important gene for human immunotherapy. It is used for the detection of inflammatory bowel diseases and cancer. It also has an important role in cancer research. The gene is involved in multiple splicing and fusion processes. Its presence in our immune system will allow us to better understand the disease and provide effective treatment. These benefits are not only significant, but the PODXL2 Gene is also associated with high levels of variability in human diseases.

The Boster Bio PODXL2 gene identifies the most likely interaction between two proteins. Researchers have identified over two thousand protein-protein interactions between yeast and DIP. This information is not complete and does not indicate the potential for protein–protein interactions. The results of this marker are promising. These studies suggest that the gene may be an effective target for cancer drug development.